Over the past few years, new-generation cell-based assays have demonstrated a robust
association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-…

Neuromyelitis optica (NMO, Devic’s syndrome), long considered a clinical variant of multiple
sclerosis, is now regarded as a distinct disease entity. Major progress has been made in the …

… Dr Kümpfel has received travel expenses and personal compensation from Bayer Schering
Pharma, Teva Pharmaceutical Industries, Merck Serono, and Biogen Idec, as well as grant …

… (A) CD4 T cells are depicted as percentage of T cells. (B–E) All other populations are
depicted as percentage of CD4 T cells. Each dot represents an individual measurement, and …

Objectives: Fatigue is one of the most common, yet poorly defined, disabling symptoms in
patients with multiple sclerosis (MS). To delineate more clearly the frequency and type of …

Objective Neuromyelitis optica (NMO) attacks often are severe, are difficult to treat, and leave
residual deficits. Here, we analyzed the frequency, sequence, and efficacy of therapies …

… This study identifies contactin-2 as an autoantigen targeted by T cells and autoantibodies
in MS. Our findings suggest that a contactin-2–specific T-cell response contributes to the …

… B-cell costimulation by activated T cells and enhanced recruitment of eosinophils. Natalizumab
was shown to increase the frequency of T cells secreting proinflammatory cytokines such …

We describe a method for correlating the immunoglobulin (Ig) proteomes with the B cell
transcriptomes in human fluid and tissue samples, using multiple sclerosis as a paradigm. …

Background: Natalizumab, a humanized anti-α4 integrin monoclonal antibody, reduces relapses
and disease progression in patients with multiple sclerosis (MS). Whereas its presumed …